0.05
0.00%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Paion
Its shares trade on Frankfurt under the ticker PA8.F. It has been listed since 11 February 2005. In the fiscal year to 31 December 2022, it reported revenue of €33.2m and a net loss of €579,000. At that date it held total assets of €38.2m and shareholders' equity of €6.6m.
PAION AG operates as a pharmaceutical company, which engages in the development of drugs to be used in out-patient and hospital-based sedation, anesthesia, and critical care services. The company is headquartered in Aachen, Nordrhein-Westfalen. The company went IPO on 2005-02-11. The firm's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In addition to that, remimazolam, which is in Phase III clinical development, can be reversed with flumazenil to terminate sedation and anesthesia, if necessary. The product can be used for general anesthesia in Europe and procedural sedation in the United States. The firm operates sites in Aachen, Germany, Cambridge, the United Kingdom, and New Jersey, the United States.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 11 Feb 2005
- Employees
- 64
- Website
- paion.com ↗
Leadership
Pay as last reported
- Mr. Michael SchlenkChairman of the Supervisory Board, since 2022$3.4m
- Mr. Gregor SiebertChairman of the Management Board, Chief Executive Officer, since 2022€15.2m
- Dr. Karin DorrepaalVice Chairwoman of the Supervisory Board, since 2012€5.2m
- Mr. Sebastian WernerChief Financial Officer, Member of the Management Board€13.1m
- Dr. Markus Leyck DiekenMember of the Supervisory Board€3.0m
- Dr. Hans TannerMember of the Supervisory Board€3.7m
- Mr. Ralf PennerIR Contact Officer, since 2023
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Remimazolam is an intravenous ultra-short-acting benzodiazepine sedative and anesthetic product.
- The firm operates sites in Aachen, Germany, and Cambridge, the United Kingdom.
- Remimazolam is metabolized by tissue esterase and not by cytochrome pathways.
Weaknesses
- The company currently employs only 64 full-time employees globally.
- Remimazolam is still in Phase III clinical development and not yet approved.
- The firm relies on a single main product for its business.
Opportunities
- The product can be used for general anesthesia in Europe.
- Procedural sedation in the United States represents a new market opportunity.
- Remimazolam can be reversed with flumazenil to terminate sedation if necessary.
Threats
- The company went public on 11 February 2005, facing market pressures.
- Development risks exist as the product remains in Phase III trials.
- Reliance on a single product line increases vulnerability to regulatory delays.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.